AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ psychedelic drug candidate, bretisilocin, targeting major depression, in a deal potentially worth up to $1.2 billion. This acquisition follows AbbVie’s recent neuroscience-focused investments, including its $9 billion purchase of Cerevel Therapeutics, whose key schizophrenia drug recently failed pivotal trials. Gilgamesh will spin off a new company retaining other drug programs, underscoring AbbVie's strategic focus on innovative psychiatric therapies.